ImmunityBio, Inc. 26CA.F Stock
ImmunityBio, Inc. Price Chart
ImmunityBio, Inc. 26CA.F Financial and Trading Overview
| ImmunityBio, Inc. stock price | 4.67 EUR |
| Previous Close | 2.54 EUR |
| Open | 2.62 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 2.58 - 2.58 EUR |
| 52 Week Range | 1.13 - 6.68 EUR |
| Volume | 2K EUR |
| Avg. Volume | 1.52K EUR |
| Market Cap | 1.15B EUR |
| Beta (5Y Monthly) | -0.337748 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.07 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25 EUR |
26CA.F Valuation Measures
| Enterprise Value | 1.81B EUR |
| Trailing P/E | N/A |
| Forward P/E | -2.931818 |
| PEG Ratio (5 yr expected) | 5.2 |
| Price/Sales (ttm) | 1963.9479 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 3082.404 |
| Enterprise Value/EBITDA | -5.199 |
Trading Information
ImmunityBio, Inc. Stock Price History
| Beta (5Y Monthly) | -0.337748 |
| 52-Week Change | -11.86% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.68 EUR |
| 52 Week Low | 1.13 EUR |
| 50-Day Moving Average | 2.51 EUR |
| 200-Day Moving Average | 3.86 EUR |
26CA.F Share Statistics
| Avg. Volume (3 month) | 1.52K EUR |
| Avg. Daily Volume (10-Days) | 420 EUR |
| Shares Outstanding | 435.98M |
| Float | 122.45M |
| Short Ratio | N/A |
| % Held by Insiders | 72.70% |
| % Held by Institutions | 12.72% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -62504.44% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -62.46% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 586K EUR |
| Revenue Per Share (ttm) | 0.001 EUR |
| Quarterly Revenue Growth (yoy) | 2471.39% |
| Gross Profit (ttm) | 240K EUR |
| EBITDA | -347424992 EUR |
| Net Income Avi to Common (ttm) | -430084000 EUR |
| Diluted EPS (ttm) | -0.97 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 91.27M EUR |
| Total Cash Per Share (mrq) | 0.21 EUR |
| Total Debt (mrq) | 766.73M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.201 |
| Book Value Per Share (mrq) | -1.213 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -346888992 EUR |
| Levered Free Cash Flow (ttm) | -244396128 EUR |
Profile of ImmunityBio, Inc.
| Country | Germany |
| State | CA |
| City | San Diego |
| Address | 3530 John Hopkins Court |
| ZIP | 92121 |
| Phone | 858 633 0300 |
| Website | https://immunitybio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 703 |
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
Q&A For ImmunityBio, Inc. Stock
What is a current 26CA.F stock price?
ImmunityBio, Inc. 26CA.F stock price today per share is 4.67 EUR.
How to purchase ImmunityBio, Inc. stock?
You can buy 26CA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ImmunityBio, Inc.?
The stock symbol or ticker of ImmunityBio, Inc. is 26CA.F.
Which industry does the ImmunityBio, Inc. company belong to?
The ImmunityBio, Inc. industry is Biotechnology.
How many shares does ImmunityBio, Inc. have in circulation?
The max supply of ImmunityBio, Inc. shares is 690.92M.
What is ImmunityBio, Inc. Price to Earnings Ratio (PE Ratio)?
ImmunityBio, Inc. PE Ratio is now.
What was ImmunityBio, Inc. earnings per share over the trailing 12 months (TTM)?
ImmunityBio, Inc. EPS is -1.07 EUR over the trailing 12 months.
Which sector does the ImmunityBio, Inc. company belong to?
The ImmunityBio, Inc. sector is Healthcare.